×
Boston Scientific ( BSX ) is trading at a sharply lower valuation after a steep decline, while Medtronic ( MDT ) has shown signs of a multi-year turnaround with its strongest revenue growth in a decade. BSX's recent pressure stems largely from a WATCHMAN slowdown, softer electrophysiology results, and a reduced 2026 outlook, offset by strength in Interventional Cardiology and Neuromodulation.
Earnings catalyst ahead: Stryker reports third-quarter results on October 29, 2026, a key test of whether its post-cyberattack recovery can extend into the back half of the year. Robotics momentum: The Mako SmartRobotics platform posted record quarterly installations, with Mako RPS entering full commercial launch and a pipeline of orthopedic and neurotechnology products scaling.
The central $365 stock price target is the arithmetic mean of the verified analyst price targets reviewed, rounded to a clean level from an underlying average near $363. With shares trading around $307, reaching $365 implies roughly 19% upside, a substantial move from current levels.
Stryker (SYK) rose roughly 12.8% over the 30 days through late October, rebounding from about $272 to close near $307. The rebound followed a sharp September 8 selloff tied to a manufacturing issue the company said was still unresolved, which reset the stock to multi-week lows.
Lead candidate advancing toward registrational trials: New interim data from the Phase 1/2a trial of VMT-α-NET (bamzireotide navoxetan) in neuroendocrine tumors is expected to shape whether the program advances into pivotal development, a central driver of the forward outlook. Expanding oncology pipeline: Beyond neuroendocrine tumors, programs targeting melanoma (VMT01) and FAP-α (fibroblast activation protein alpha) positive solid tumors (PSV359) broaden the company's addressable market and diversify clinical risk.
Acquisition-led scale remains the core driver: INVO Fertility is pursuing a disciplined roll-up of established, profitable U.S. fertility clinics, with management describing a robust pipeline of potential targets. Organic growth complements deal flow: patient-volume expansion, added services, physician recruitment, and telehealth are intended to lift revenue across existing clinics in 2026 and beyond.
Regulated device pipeline is the core near-term catalyst. U.S. launches of the Libre Duo glucose-ketone sensor, the Amulet 360 left atrial appendage device, the TactiFlex Duo PFA (pulsed field ablation) catheter, and a coronary IVL (intravascular lithotripsy) system are expected to re-accelerate Medical Devices growth into late 2026 and 2027. The Exact Sciences acquisition reshapes Abbott's diagnostics positioning. Completed in March 2026, the deal adds Cologuard, Cancerguard, and Oncotype DX, positioning Abbott across the cancer-screening continuum and creating a new structural growth engine.
The central $12 stock price target is the arithmetic mean of recently published analyst price targets for Perspective Therapeutics, Inc. (CATX) , a clinical-stage radiopharmaceutical developer. The target is drawn from a wide range of roughly $5 to $18 across about 16 analysts, whose average recommendation is a "Strong Buy."
The central target used here is $1.00 , a market-structure milestone tied to Nasdaq's $1.00 minimum bid price rule and a psychological round number, rather than an analyst-derived price target. From a recent close near $0.64 , reaching $1.00 would require a gain of roughly 56% , a substantial move for a heavily diluted micro-cap.
The $150 central target is the arithmetic mean of roughly a dozen verified analyst price targets issued between late 2025 and early 2026, spanning an approximate range of $140 to $162. With the stock recently trading near $100.50, reaching $150 would require a gain of about 49%, a very large move relative to the current price.
Perspective Therapeutics (CATX) shares fell roughly 39% over the last 30 days, sliding from $2.62 on September 23 to $1.61 at the October 23 close. The bulk of the decline came in a single session on October 23, when the stock dropped about 29% following interim Phase 1/2a data for VMT-α-NET presented at ESMO 2026.
INVO Fertility (IVF) shares fell roughly 44% over the trailing 30 days, sliding from about $1.02 to $0.57. The decline extends a much longer downtrend: the stock is down approximately 98% over the past 52 weeks and trades near its 52-week low.
Abbott Laboratories (ABT) traded near $103.70 in late October 2026, up roughly 2.6% over the trailing 30 days after a choppy stretch for the stock. The shares pulled back from above $116 in late August to the mid-$90s in early October before stabilizing and recovering modestly into earnings season.
Guidance reset is the near-term focal point: Management has lowered 2026 expectations to 5%–6% organic revenue growth and adjusted earnings per share (EPS) of $3.28–$3.32, citing a slower U.S. WATCHMAN market and greater-than-expected electrophysiology (EP) share losses. Recovery is being teed up for 2028: Boston Scientific is pointing to seven new launches addressing roughly $25 billion in total addressable market (TAM), including the SEISMIQ 4CE coronary intravascular lithotripsy (IVL) catheter expected in the first half of 2027.
The central target of $53 is the arithmetic mean of eight recent, individually identified analyst price targets, which range from $48 to $65. The latest verified price of about $45.70 means reaching $53 would require a roughly 16% advance — a modest move by typical single-stock standards.
Boston Scientific shares have held a modest gain of about 2.3% over the trailing 30 days, moving from roughly $44.68 to $45.69, well below the threshold that signals a sharp price breakout. The company beat Wall Street estimates in its latest quarter, yet lowered full-year 2026 guidance, reflecting slower WATCHMAN demand and U.S. electrophysiology share losses.
POAS shares fell -15.11% during regular trading, sliding from a $2.25 prior close to roughly $1.91. The decline extends post-reverse-split weakness following the 1-for-15 reverse stock split that took effect October 12.
CATX fell -25.22% to $1.69 in regular trading, versus a prior close of $2.26. The drop followed its ESMO 2026 interim readout for [212Pb]VMT-α-NET, a classic "sell the news" reaction despite upbeat headline data.
QDEL is trading down -6.01% to $12.67 during regular market hours, extending a -4.26% decline from the prior session close of $13.48. The move reflects ongoing pressure from China's proposed IVD pricing guidelines and softer respiratory testing demand, which drove a lowered 2026 outlook after the Q2 report.
Integer Holdings is expected to report its third-quarter 2026 results on Thursday, October 22, in what is widely viewed as its final public earnings report before going private. Wall Street consensus points to adjusted earnings per share (EPS) of $1.69 on revenue of roughly $457.8 million for the quarter.
Previous
22 of 31
Next